This site is intended for healthcare professionals
News

Less than 1% of patients treated with Calquence discontinued treatment due to cardiac adverse events in pooled analysis of chronic lymphocytic leukaemia patients.- AstraZeneca

Read time: 1 mins
Last updated:8th Dec 2020
Published:8th Dec 2020
Condition: CLL/SLL
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest